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Abstract
Fitness interactions between mutations, referred to as epistasis, can strongly impact evolution. For RNA viruses and
retroviruses with their high mutation rates, epistasis may be particularly important to overcome fitness losses due to the
accumulation of deleterious mutations and thus could influence the frequency of mutants in a viral population. As human
immunodeficiency virus type 1 (HIV-1) resistance to azidothymidine (AZT) requires selection of sequential mutations, it is a
good system to study the impact of epistasis. Here we present a thorough analysis of a classical AZT-resistance pathway (the
41–215 cluster) of HIV-1 variants by fitness measurements in single round infection assays covering physiological drug
concentrations ex vivo. The sign and value of epistasis varied and did not predict the epistatic effect on the mutant
frequency. This complex behavior is explained by the fitness ranking of the variants that strongly depends on environmental
factors, i.e., the presence and absence of drugs and the host cells used. Although some interactions compensate fitness
losses, the observed small effect on the relative mutant frequencies suggests that epistasis might be inefficient as a
buffering mechanism for fitness losses in vivo. While the use of epistasis-based hypotheses to make general assumptions on
the evolutionary dynamics of viral populations is appealing, our data caution their interpretation without further knowledge
on the characteristics of the viral mutant spectrum under different environmental conditions.
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Introduction
Epistasis, the fitness interaction between mutations, has been
suggested to influence the evolutionary dynamics of virus
populations [1]. In its original definition by Bateson, epistasis
described a phenomenon in which a discrete phenotype derived
from a genetic variant in one locus was altered by a genetic
variant at another locus [2]. Thus both loci must be located
within the same phenotype-determining gene clusters and show
some kind of interaction. With this mechanism in mind, epistasis
is nowadays commonly used to describe any deviation from an
expected phenotype that originates from a combination of
mutations.
Fitness interactions can act in different directions. If mutations
interact such that their combined effect on fitness is greater than
expected from their individual effects, then epistasis is said to be
synergistic. By contrast, if mutations interact so that their
combined effect is smaller than expected, then epistasis is called
antagonistic. Depending on the nature of the mutations being
deleterious or beneficial, the sign of epistasis can be positive or
negative. When mutations are deleterious, synergistic interactions
result in negative epistasis and antagonistic interactions result in
positive epistasis. The contrary is true for beneficial mutations
were synergistic interactions result in positive epistasis and
antagonistic interactions result in negative epistasis [3,4].
Epistatic effects have been observed in many fundamental
biological processes like speciation [5], long-term selection in
model organisms [6], and in loci associated with human diseases
[7–9]. Epistatic interactions also have a central role in evolution-
ary topics such as the evolution of sexual reproduction [10,11] and
the structural evolution of genetic systems [12,13]. With respect to
viruses, interactions between mutations are also common. Epistasis
among viral loci has been found in many diverse viruses like DNA
bacteriophage Phi-X174 [14], RNA bacteriophage Phi-6 [15],
foot-and-mouth disease virus [16], polio virus [17], vesicular
stomatitis virus [18], chikungunya virus [19] and human
immunodeficiency virus (HIV) [20–24]. Although a wide range
of interactions (positive and negative) was observed, a predomi-
nance for positive epistasis seems to be the trend which may
directly impact viral robustness and the efficiency of variant
selection under therapy [1,3,18,25,26]
HIV is an ideal candidate to study epistatic interactions in
viruses. First, the virus shows a phenomenal genetic diversity
which is observed at all possible levels from between patient
comparisons to variants even within multi-infected individual cells
[27]. This genetic diversity is accompanied by the capacity of HIV
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to rapidly adapt to changing environments. It is best exemplified
by the rapid selection of escape mutants in response to antiviral
drugs. Depending on the nature of the drug-HIV interaction, it
may require just few weeks to fix the resistant mutants within the
viral population in vivo [28]. Second, HIV grows easily in cell
culture and assays to determine viral fitness are well established.
Third, there is ample data on HIV sequences and characteristics
within patients that allow estimating the consequences of epistatic
interactions within infected hosts.
Under the conditions of mutation-selection equilibrium, fitness
interactions between mutations will affect the frequency of
individual mutants within a virus population. A buffering effect
of deleterious mutations is expected if epistasis would be positive.
In this case, the abundance of deleterious mutants would be higher
than expected and the viral population may respond faster to a
new selection pressure supposing that the deleterious mutations
would be beneficial under the new growth conditions. A clinically
important example and test scenario for this is the selection of
drug-resistant HIV variants after the use of antiretroviral
treatment. By using amino acid sequence data of the reverse
transcriptase and protease regions of HIV-1 isolates from infected
individuals undergoing antiviral treatment, and the corresponding
fitness values measured in vitro in the absence of drugs, statistical
evidence for the predominance of positive epistasis has been
detected [20]. However, a number of limitations of this study have
been raised. One major concern was the likely under-representa-
tion of low fit variants in the data set that could have led to false
conclusions towards epistasis [29]. Such a biased genome
representation seems inevitably linked to the experimental
procedure used to generate the genotype to phenotype correla-
tions. A preference for the major viral mutants and thus more fit
variants is simply obtained by PCR-mediated amplification and
the direct cloning of the respective HIV regions into HIV vectors
for subsequent fitness measurements. Thereby the clonal sequence
representation is expected to be directly proportional to the
respective fitness of the variant in vivo. Other limitations of the
study were (i) the lack of fitness values in the presence of drugs so
that epistatic effects and their consequences could not be
compared with and without medication and (ii) the lack of
knowledge of the direct path of mutation accumulation including
all intermediate mutants.
A straightforward and complementary approach to measure
fitness interactions relies on the construction of HIV variants with
all mutations along an evolutionary pathway, then measuring their
individual and combined fitness effects, and comparing the results
with predictions generated under the null hypothesis of non-
epistatic interactions [18]. While this approach is experimentally
feasible only for a limited number of variants and thus lacks
completeness over all possible HIV mutation pathways, it is of
highest resolution and captures all variants including those of very
low fitness. Here we report the results of such an analysis of a
specific mutation pathway that HIV follows within individuals
after treatment with azidothymidine (AZT), a nucleoside-analog
reverse transcriptase inhibitor. The overall aim was (i) to generate
a complete and physiologically relevant HIV data set with fitness
values for all mutants within the mutation pathway, (ii) to
determine the influence of environmental factors like host cells
and antiviral drug concentrations on the fitness interactions of the
mutations and (iii) to derive quantitative estimates of the epistatic
effects on the relative frequency distribution of the viral mutants.
The determined fitness values match the HIV mutant frequencies
observed within patients and can explain the observed mutation
pathway. Epistatic interactions depend strongly on the host cell
environment and decrease with increasing drug concentrations.
The relationship between the value of epistasis and the relative
mutant frequency is complex and determined by the fitness
ranking of individual mutants.
Results
Selection of a HIV-1 mutation pathway for analysis of
epistatic interactions
In order to quantify precisely epistatic interactions in HIV and
analyze their dependence on environmental factors such as host
cells and antiviral drugs, we focused on a specific mutational
pathway that HIV-1 follows in vivo during treatment with AZT, the
prototypic reverse transcriptase (RT) inhibitor first used in infected
patients and a common component of current anti-retroviral
formulations. When taken up by cells, AZT is phosphorylated by
thymidine kinases to the active AZT-triphosphate. Upon incor-
poration into the nascent HIV DNA strand, RT-dependent chain
elongation is stopped due to the 39azido-group [30]. Treatment of
HIV-infected individuals with AZT leads to the selection of AZT-
resistant HIV-mutants with defined amino acid changes in the
RT. The mechanism of resistance development is well studied
[31,32] and follows specific pathways. One such HIV-1 resistance
pathway (Figure 1) is characterized by the key mutations at
positions 41 and 215 of the RT [31,33]. The highly AZT-resistant
double mutant M41L-T215Y appears in vivo after around 255
weeks of treatment and requires a number of intermediate mutants
of which only the M41L and T215Y mutants are commonly
observed [31]. However, at least one of the other possible
intermediates, T215S, T215N, M41L-T215S and M41L-T215N
must have been transiently generated (Figure 1, in grey).
Generation of AZT-resistant mutants of HIV-1, fitness
determination and epistasis calculations
All seven HIV-1 RT mutants from an AZT-resistance pathway
(Figure 1) were generated by shuffling PCR. They were then
cloned into an HIV-1 NL4-3-based vector that is deficient in the
expression of a functional envelope (Env) protein and contains the
Renilla luciferase gene in the position of nef [34]. Respective HIV-1
Env-pseudotyped viruses that can only undergo a single round of
infection in susceptible target cells were subsequently produced
from 293T cells after co-transfection with RT mutants and an
HIV-1 env expression plasmid. The relative fitness of the mutant
viruses was assessed under a range of physiologically relevant AZT
concentrations by infecting the TZM-bl cell-line or primary
peripheral blood lymphocytes (PBMCs) from two healthy donors
(here referred to as donors 1 and 2) and measuring the relative
luciferase activities of the variants compared to that of the wild-
type. The epistatic interaction E of the mutations was then
calculated according to the epistasis definition in a two-locus-two-
allele model: E=W00W112W01W10 [Equation 1], where W00 is
the fitness of the wild type, W11 the fitness of the double mutant
and W01, W10 are the fitness of both single mutants, respectively.
Observed and expected relative fitness values were then
graphically compared as described previously [3,24].
The fitness ranking of AZT-resistant HIV-1 RT mutants
corresponds to their frequency distribution in AZT-
treated patients
The distribution of fitness relative to that of the wild type for all
single and two-point HIV-1 RT mutants infecting TZM-bl cells or
PBMC in the presence of 0 to 10 mM AZT is shown in Figure 2
and in Figure S1 and Table S1 under Supporting Information.
With the TZM-bl cell line and the PBMC of two blood donors as
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target cells, the wild-type virus has a varying fitness advantage over
the AZT-resistant variants in the absence of drug. Increasing drug
concentrations render particularly the mutants M41L, T215Y and
M41L/T215Y more fit than the wild type. These dominant RT
mutants have been analyzed previously and our determined
relative fitness values are concordant with previous findings
[35,36]. Similarly concordant are the inhibitory concentration
50 (IC50) values for AZT that have been determined for these
mutants [35,37–40] and which can be derived from our fitness
measurements as a function of drug concentrations. The newly
analyzed intermediate mutants T215S, T215N, M41L-T215S and
M41L-T215N of the AZT-resistance pathway (Figure 1) exhibit
low fitness values under all drug concentrations with the 215S
mutants being slightly fitter than the 215N. Thus, taken together,
Figure 1. Mutation pathway of the HIV-1 reverse transcriptase under AZT therapy in vivo. The scheme shows one common in vivo
developmental pathway of AZT-resistant HIV-1 mutants at amino acid positions 41 and 215 in the reverse transcriptase. Amino acids are given in the
one letter code. In the block arrow, estimated waiting times of mutant appearance are marked. The values are according to estimations from
Beerenwinkel, et al. [31] The flowchart arrows highlight the respective nucleotide changes. Mutants found in vivo are in bold type while mutants in
grey are not observed in vivo.
doi:10.1371/journal.pone.0018375.g001
Figure 2. Relative fitness values of HIV-1 reverse transcriptase mutants along an AZT-resistance pathway. Mean fitness values for wild
type (WT) and mutants in the TZM-bl cell line and PBMC from Donor 1 and Donor 2 as a function of AZT concentration. The values are the mean of
three or four independent infections (the actual values with standard deviations and errors are given in Table S1 and plotted in Figure S1 under
supporting information). The mean fitness of the wild type without the addition of drug was set to 1. AZT concentrations range from 0 to 10 mM
which cover the physiologically relevant range in vivo.
doi:10.1371/journal.pone.0018375.g002
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the ranking order of the fitness values for all RT mutants in the
presence of AZT correspond well with the frequency distribution
of the respective mutants found in patients under AZT treatment
i.e. T215Y . M41L . T215S . T215N (Stanford Drug
Resistance Database, http://hivdb.stanford.edu).
The fine structure of the fitness distribution of the RT mutants
in TZM-bl and PBMC revealed interesting features that are best
visualized in supplementary figure S1. (1) The relative fitness of
the AZT-resistant mutants is influenced by the host-cell
environment. For example, the mutants T215Y and M41L-
T215Y exhibit a higher relative fitness without drug in PBMC of
donor 2 than in PBMC of donor 1 or TZM-bl cells. Furthermore,
with the exception of the M41L-T215S, the non-dominant RT
mutants are fitter in TZM-bl cells under all AZT concentrations
than in PBMC. (2) The fitness of the wild type in the presence of
AZT is usually higher in PBMC than in TZM-bl cells. This
mounts to an about 10-fold and 30-fold difference under 2 mM
and 5 mM AZT respectively. Under 10 mM AZT, the replication
of the wild type was practically not detectable in all cell-types. (3)
The fitness differences between the wild type and the RT mutants
are not constant. For example, with 5 mM AZT, the highly
resistant mutant M41L/T215Y exhibits a 160-fold higher fitness
than the wild type in TZM-bl cells but is only around 6-fold or
20-fold fitter in PBMC of donor 1 and 2, respectively. Thus, the
fitness behavior of the wild type and the RT mutants as a
function of AZT concentrations is cell type dependent. This
correlates well with the observation that HIV replication and
adaptation strongly depends on the host-cell environment
[41–43].
The HIV-1 AZT-resistance pathway is characterized by
strong and varying epistasis between the RT mutations
at amino acids 41 and 215
In order to analyze possible interactions between the mutations
of the key amino acids along the AZT-resistance pathway, we
calculated epistasis (E) according to equation 1 from the
determined fitness values. Without drug pressure, E is always
strongly positive for the TZM-bl cells and both PBMC Donors
(Table S2, under Supporting Information) however the relative
values for the three double mutants differ in the target cells. To
better visualize the epistatic interactions between all RT
mutations, the experimental fitness values of the double mutants
(i.e. the observed fitness) were plotted against the products of the
fitness of the one-point mutants (i.e. the expected fitness under the
assumption of no epistatic interactions) (Figure 3A). Positive
epistasis means that the fitness of the double mutants is higher than
expected (the diagonal line corresponds to no epistatic effects). To
test whether the overall finding of epistatic interactions is
statistically robust, we performed bootstrapping to generate
randomized data sets (N= 1000) and applied the same analysis.
In all cases the mean epistasis values were significantly greater
than zero (Table S2 under Supporting Information).
Figure 3. Epistasis in AZT-resistant HIV-1 reverse transcriptase mutants. (A) The observed relative fitness of double mutants W11 along an
AZT resistance pathway under different AZT concentrations is plotted against the product of the relative fitness of the single mutants W10xW01. The
latter reflect the expected fitness if there is no epistasis. Values are calculated for the fitness in TZM-bl cells and PBMC from two healthy donors
(named Donors 1 and 2). The diagonal line corresponds to absence of epistasis while the areas of positive and negative epistasis are above and below
respectively. Error bars indicate standard error of the mean. (B) Positive epistasis declines in strength with increasing AZT concentrations. Epistasis
values for the three HIV-1 double mutants along the AZT resistance pathway are plotted against AZT concentrations. Error bars indicate standard
error of the mean.
doi:10.1371/journal.pone.0018375.g003
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The epistatic interactions between the mutations
changed upon increasing drug pressure and differed
between the target cells used
An increase in AZT concentrations resulted in a decrease of
epistasis. The three different double mutants showed a varying
relative decrease in the different target cells. With TZM-bl cells,
the sign of epistasis changed to negative already from the lowest
AZT concentration whereas with the PBMC of donors 1 and 2,
epistasis was mainly (donor 1) or always (donor 2) positive
(Figure 3B). The change in the sign of epistasis in the TZM-bl cells
is mainly due to the fitness ranking of the wild type, which is
relatively low, and the 1-point mutants, which are relatively high
in these cells as compared to PBMC (see Supporting Figure S1).
Together these observations show that the type of fitness
interaction may change along with the environmental conditions
under which it is analyzed. In the absence of drug, the fitness loss
due to the acquisition of resistance mutations is compensated by a
strong antagonistic interaction (positive epistasis) in all cases.
However when AZT is present, the fitness interaction is still
antagonistic (now negative epistasis) in TZM-bl cells but becomes
mainly synergistic (now positive epistasis) in PBMC. Thus the
fitness gain is less than expected for TZM-bl cells but mainly
higher than expected for PBMC.
Epistasis affects the relative abundance of drug-resistant
HIV-1 mutants
The fitness interactions between the mutations along a drug-
resistance pathway are expected to have an impact on the relative
mutant frequencies in a viral population. This in turn may be of
great clinical importance for the selection of drug-resistance under
antiviral treatment because a higher or lower steady state level of a
resistant mutant may lead to a faster or slower outgrowth. Having
determined all fitness values for all mutants along the AZT-
resistance pathway, we were now able to quantitatively estimate
the effect of epistasis on the relative abundance of the double
mutants. For this, the expected fitness values under the assumption
of no epistasis were calculated from the experimentally determined
fitness values and used to analyze the respective steady state
frequencies assuming a mutation-selection equilibrium as defined
by the general model of HIV quasispecies dynamics [44]. Under
this condition, the relative abundance of the wild-type virus and
the 1-point and 2-point mutants can be estimated by computing
the eigenvectors of the following eigenvalue problem [Equation 2]:
(1{m1)(1{m2)W00 (1{m1)m2W01 m1(1{m2)W10 m1m2W11
(1{m1)m2W00 (1{m1)(1{m2)W01 m1m2W10 m1(1{m2)W11
m1(1{m2)W00 m1m2W01 (1{m1)(1{m2)W10 (1{m1)m2W11
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Here, y00 and y11 denote the equilibrium abundance of the wild-
type virus and the 2-point mutant, respectively, whereas y01 and
y10 denote the equilibrium abundance of the 1-point mutants. The
parameters m1 and m2 characterize the mutation rate for the first
position and for the second position respectively, l is the standard
notation for the eigenvalue. Under the simplifying assumption that
the mutation rate m is not affected by the mutations itself, the
relative frequencies of the 2-point mutants can be readily
calculated using our fitness data (Table S1) and MATLAB
routines (www.mathworks.com). The results are shown in
Figure 4 and Table S3.
Depending on the AZT concentration, the presence of epistasis
has a marginal or a significant effect on the relative frequency
distribution of the 2-point mutants within the virus population.
Importantly, high epistasis values do not directly predict a large
effect on that distribution. For example, without AZT when
epistasis is highest, the relative mutant frequencies are around
1028 to 1029 and epistasis affect those frequencies up to 3-fold
(Figure 4 and Table S3). In the presence of AZT when epistasis
values were significantly smaller, frequency effects of up to around
104-fold are observed. Taking the M41L/T215Y mutant in the
presence of 0.03 mM AZT as an example, epistasis increased the
relative frequency around 104-fold according to the measurements
in PBMC of donor 2 (Table S3c), diminished it around 104-fold
according to the measurements in TZM-bl (Table S3a) or left it
relatively unchanged (PBMC donor 1, Table S3b). Furthermore,
the frequency effects were not linear. Taking again the M41L/
T215Y mutant, epistasis increased the relative frequency around
104-fold at 0.03 mM AZT and 2 mM AZT, however had nearly no
effect at 0.3 mM AZT. This complex behavior is due to the fact
that the epistasis effect on mutant frequencies strongly depends on
the distribution of the relative fitness values for wild type,
intermediate mutants and the 2-point mutant, i.e. their ranking.
If the intermediate one-point mutants (at least one of them) have
larger fitness value than the two-point mutant would have in the
absence of epistasis then the effect would be strong. Otherwise the
two-point mutant will dominate with and without epistasis. Let us
consider two examples: Under 0.3 mM AZT in PBMC of donor 2,
the fitness values for wild type, M41L, T215Y and M41L-T251Y
are 0.16260.010, 0.16660.013, 0.29360.014 and 0.38560.047,
respectively (see Table S1c for all values of the standard errors of
the mean and Table S4 for evaluation of the significance of the
fitness differences). Thus, one would expect that the M41L-T251Y
mutant will dominate because of its highest fitness and its relative
frequency is expected to be close to 1 (in fact 0.999; Table S3c).
Assuming no epistatic interaction, the relative fitness for the same
variants are 0.16260.010, 0.16660.013, 0.29360.014 and
0.30060.069, respectively. The M41L-T251Y mutant still dom-
inates because it has the highest fitness and its relative frequency is
close to 1 (0.998). In the case of 2 mM AZT, the fitness values with
epistasis are 0.042660.0027, 0.023660.0029, 0.11660.0078 and
0.18760.010, respectively. The M41L-T251Y mutant will
dominate with a relative frequency close to 1 (in fact 0.999).
Assuming no epistasis, the relative fitness is 0.042660.0027,
0.023660.0029, 0.11660.0078 and 0.064260.020, respectively.
Now the 1-point T251Y mutant will dominate because it has the
highest fitness and its relative frequency is expected to be close to
1. In this case the relative frequency of the two point mutant
M41L-T251Y is only 0.0000897. Thus the epistatic effect is large
although the epistasis value is small (Figure 3B and Figure 4).
Discussion
Epistasis is a fundamental component of the genetic architecture
of biological entities and has been suggested to influence the
evolutionary dynamics of virus populations. Here we have
quantified the fitness of all HIV-1 mutants along the classical
AZT-resistance pathway under physiological drug concentrations
ex vivo, calculated the epistasis values and estimated its impact on
mutant frequencies within the viral population. Overall, the
pattern of epistasis is complex and dependent on the drug
concentrations and the host cells used. Without AZT, epistasis is
consistently positive within the TZM-bl cell line and the PBMCs of
Fitness Ranking and Epistasis in HIV-1
PLoS ONE | www.plosone.org 5 March 2011 | Volume 6 | Issue 3 | e18375
both blood donors, and results in an estimated 1.5 to 2.8-fold
increase in the ratio of the highly resistant 2-point mutant M41L-
T251Y to wild type. The presence of AZT leads to a
concentration-dependent decrease of epistasis. This is due to the
fitness decrease of all variants especially the wild type in the
presence of AZT and the respective reduction of the difference of
their products (see equation 1 and figure 2). Furthermore, the signs
and values of epistasis differ depending on the host cells used and
the numerical values do not predict the epistatic effect on the
mutant frequency. This complex behavior is explained by the
fitness ranking of all mutants in the presence of AZT and the
uneven fitness distribution of the 1-point mutants.
Figure 4. Effect of epistasis on the relative frequencies of drug-resistant HIV-1 mutants. The plot shows the estimated relative frequencies
of the double mutants along the AZT resistance pathway under different AZT concentrations for TZM-bl cells and both PBMC donors without
epistasis (black bars) and with epistasis (grey bars). Without drug pressure, epistasis has a small effect on the mutant frequencies. With the addtion of
drug, epistasis has a varying effect on the mutant frequencies that is dependent on the fitness ranking of the wild type, 1-point mutants and 2-point
mutants. Calculations were performed according to an established model specified in equation 2 (see text for details). Fitness values were taken from
Table S1.
doi:10.1371/journal.pone.0018375.g004
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The observed positive epistasis under drug-free conditions has a
buffering effect on the mutant distribution and caused an increase
of the relative frequency of the highly AZT-resistant 2-point
mutant M41L-T251Y over the expected frequency if epistasis
would be absent. However this relative frequency increase from
about 161028 to about 3.661028 (see Table S3) within the virus
population is only marginal considering the published estimates of
the HIV effective population size in vivo of around 103 to 104 [45].
In the presence of AZT, the sign of epistasis varies with the drug
concentrations and the host cells used. As a consequence, epistasis
increases or decreases the relative 2-point mutant frequencies or
leaves it relatively unchanged. For example, under 0.03 mM AZT
and TZM-bl as host cells, epistasis decreases the relative frequency
of M41L-T215Y from 1 to 5.561024, whereas with PBMC from
Donor 2, epistasis increases the relative frequency from 4.561024
to almost 1. Although these estimated relative frequencies are now
in the range of the effective population size of HIV in vivo, a
condition where epistatic effects are expected to be relevant, there
are no consistent biological criteria to derive general statements on
the importance of the epistatic effects for the mutant frequency at
the population level.
Epistasis was suggested to contribute to viral robustness, the
ability of a virus to maintain stable functioning despite genetic and
environmental perturbations [1,25]. In general, single mutations
in a viral genome are deleterious and will reduce viral fitness. The
observed predominance of positive epistasis among viral genomes
suggests a buffering effect for subsequent mutants such that the
mutant spectrum is enlarged [25,46,47]. This in turn may become
beneficial for the virus population in the context of a strong
selection pressure like antiviral treatment. However as we show
here for the mutants along the AZT resistance pathway, the
buffering effect without AZT is so low that positive epistasis is
unlikely to be a major contributing factor to the robustness of HIV
i.e. to allow low fitness mutants to survive in an HIV population in
vivo. Other mechanisms than epistasis may be considered as of
prime importance within infected individuals. First, the HIV
provirus can persist for months independent of the replicative
capacity of the respective mutant [48]. Second, multi-infection of
single cells in vivo is common and thus phenotypic mixing can
contribute to mutant survival [27,49]. The recent suggestion that
HIV is evolving towards a more robust population due to the
selection of a lower fitness landscape is compatible with such a
scenario [26,50].
The development of drug resistance in HIV infection remains
one of the most challenging difficulties in antiviral treatment. The
dynamics of resistant mutants depends on a number of virus
replication parameters such as the fitness values, the number of
available target cells and mutation/recombination rates. Although
the interplay between these factors has been studied using
mathematical models, their results suffer from not being based
on exact values for all parameters. Fitness is a major determinant
of the selection process of drug-resistant mutants that is amenable
to experimental quantification. In this respect, the fitness estimates
for a complete spectrum of AZT-resistant mutants as a function of
the drug concentrations obtained in our work established a solid
quantitative basis for further data-driven in silico studies.
In summary, our study provides high-resolution fitness values
along an important HIV drug-resistance mutation pathway and
quantifies the impact of epistasis on mutant frequencies. The
pattern of epistatic interactions between the specific mutations is
complex and dependent on environmental factors such as the
presence and absence of drugs and the host cells used. While some
interactions compensate fitness losses, the effect on the relative
mutant frequencies was small so that epistasis as a buffering
mechanism for fitness losses might be rather inefficient. Together
these data caution against over-interpreting qualitative data on
epistasis for evolutionary dynamics of viruses without knowledge of
the fitness ranking of the complete mutant spectrum.
Materials and Methods
Experimental Design
To measure the fitness of HIV-1 RT mutants along an AZT
resistance pathway and to evaluate the effect of epistasis ( = the
fitness interactions between the mutations), we generated the
respective RT mutants by site-directed mutagenesis PCR [51].
They were then cloned into the HIV-1 viral vector TN7-Stopp
that carries the Renilla luciferase reporter gene instead of nef and
lacks a functional env gene [34]. HIV pseudotypes were produced
by co-transfection of 293T cells with an HIV-1 env expression
plasmid. The fitness values of the mutants were quantified by
measuring the replication capacity of the mutants as the % relative
luciferase activity, compared to that of the wild type, after single
round infection of target cells with and without the addition of
AZT.
Generation of wild type and drug resistant mutants
Mutagenesis. PCR site-directed mutagenesis was used to
introduce the desired nucleotide changes at codons 41 and 215 of
the reverse transcriptase gene of the HIV-1 NL4-3 molecular
clone. This technique involves two PCR reactions using
overlapping primers (see Table S5 for primer details). Briefly, in
the first PCR, a 1062 base pair fragment containing the desired
region was amplified using a 59 primer carrying a unique
restriction site for BclI and the 39 overlapping primer carrying
the desired RT mutation. In parallel, another PCR used the 39
primer carrying the restriction site for AgeI and the 59 overlapping
primer carrying the other desired RT mutation. The resulting
fragments were isolated from an agarose gel and used as templates
in the second PCR with only the 59 BclI and the 39 AgeI primers
giving rise to the final template. The thermocycling conditions for
the first PCR were 94uC for 2 min followed by 30 cycles of 94uC
30 s, 58uC 30 s (50uC for the second PCR) and 68uC 45 s (72uC,
1 min for the second PCR) and then a final elongation step of
68uC for 7 min. The introduced restriction sites were used for the
subsequent cloning of the mutated fragment.
Plasmids and cloning. The PCR products were ligated into
the pGEM-T vector (Promega) via TA cloning following
manufacturer’s instructions. E. coli ER2925 (Stratagene) were
then transformed and selected on ampicillin agar plates. Plasmid
DNA was extracted using the alkaline method. Samples were run
on an agarose gel, isolated and sequenced by dideoxy-sequencing.
Plasmids containing the desired RT mutants were digested with
AgeI and BclI (New England Biolabs) and the respective fragments
were inserted into the pTN7-Stopp HIV-1 expression plasmid
using the same restriction sites. pTN7-Stopp is derived from the
HIV-1 NL4-3 based viral vector and has the luciferase gene in the
position of the nef gene [34]. It is designed for a single round of
replication since it does not express the envelope gene due to the
insertion of two nucleotides in the 59region of the signal peptide
resulting in a frameshift and premature termination of translation.
Generation of HIV-1 pseudovirus stocks. For pseudo-
typed virus generation, wild type or mutated pTN7-Stopp
plasmids were co-transfected with a specific plasmid expressing a
CCR5-tropic HIV-1 envelope gene into the 293T cell line [52].
Briefly, 293T cells (106 cells) were transfected with 4 mg of each
plasmid DNA using Lipofectamine (Invitrogen) according to the
manufacturer’s instructions. 48 hours after transfection, virus-
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containing supernatants were harvested, filtered with 0.45 mm
cellulose-acetate filters (Schleicher & Schuell), titrated and stored
in 1 ml aliquots at 280uC until use.
Range of AZT concentrations. We used AZT at final
concentrations of 0, 0.03, 0.3, 2, 5 and 10 mM for the infection
experiments. These cover the physiological concentrations of anti-
retroviral therapy [53,54].
HIV-1 pseudotype infections and determination of
relative fitness. Target cells for infection experiments were
peripheral blood mononuclear cells (PBMCs) from healthy blood
donors and TZM-bl cells. TZM-bl is a HeLa cell line, which
expresses CD4 and both CCR5 and CXR4 co-receptors [55,56].
Cells were plated in triplicate or quadruple on 96 well plates at a
density of 105 cells/well and left untreated (0 mM AZT) or pre-
incubated for 2 hours with AZT at the final concentrations
mentioned above before infections. PBMCs from healthy donors
were stimulated overnight with PHA prior to the drug incubation.
Infections were performed for each drug treatment by adding
wild-type and mutant virus at an MOI of 0,5 in 100 ml of medium
to untreated or treated cells. Forty-eight hours after infection, cells
were washed and assayed for luciferase activity with the Luciferase
Reaction Kit (Promega) according to the manufacturer’s
instructions. In addition, the relative luciferase activities from
infections were normalized to the transfection efficiencies of 293T
cells during HIV pseudotype preparation. The final relative fitness
values for all mutants were the obtained by relating them to the
fitness of the wild type (see below).
Statistical analysis. The method of estimating the mean
fitness value for every mutant and AZT dose was performed as
following: (i) the mean value of a given number of independent
measurements of RLU/s was estimated (RLUmutant); (ii) the
mean background value, i.e. control (RLUcontrol) was calculated
to (iii) correct the original value for the background by subtracting
it (RLUcorrected =RLUmutant-RLUcontrol) and then (iv) to
normalize the corrected replication capacity using the transfection
efficiency parameter, teff, thus getting absolute fitness estimate
fabs =RLUcorrected/teff. Finally, the absolute fitness estimates
were normalized with respect to the absolute fitness value of the wt
genome without drug (f0): f = fabs/f0. The above estimates of the
mean of the mutant fitness by using the sample means were
supplemented by evaluating their sample variances using the
formulas for variances of the products and ratios of independent
random variables [57]. The donor cell data were used to estimate
the mean fitness and variance values for each mutant using
standard formulas for the mean and variance of the sum of
independent random variables. To evaluate the epistasis values
two different approaches were used. One is based upon a direct
calculation of the mean and variance values using the epistasis
formula and the rules for dealing with the functions of random
variables [57]. The second one implements a parametric bootstrap
method to make inference about the mean and its associated
standard error. To this end a normal distribution with the
corresponding estimated sample mean and variance was used to
draw the fitness values of wt, single- and double mutant genomes
with the size of the generated sample of 1000. The 95%
confidence intervals shown in Tables S1 and S2 under
Supporting Information were calculated using the bootstrap
estimates of the standard deviation (SD) as mean 61.96*SD.
Supporting Information
Figure S1 Bar-plot showing the comparative and high-resolu-
tion cell-to-cell fitness distribution of the wild type and RTase 1-
point and 2-point mutants along an AZT resistance pathway
under different AZT concentrations. Error bars are standard error
of the mean.
(TIF)
Table S1 Complete set of the relative fitness values and statistics
for the wild type and RTase 1-point and 2-point mutants along an
AZT resistance pathway measured under different AZT concen-
trations in the TZM-bl cell line (a), Donor 1 (b) and Donor 2 (c).
(DOC)
Table S2 The calculated epistasis values and statistics for the
RTase 2-point mutants along an AZT resistance pathway under
different AZT concentrations in the TZM-bl cell line (a), Donor 1
(b) and Donor 2 (c). Calculations were made according to equation
1 (see main text and materials and methods for details).
(DOC)
Table S3 Relative frequency values for the RTase 2-point
mutants along an AZT resistance pathway under different AZT
concentrations in the TZM-bl cell line (a), Donor 1 (b) and Donor
2 (c). Relative frequencies with positive epistasis are noted in bold
and with negative epistasis in italic. Frequencies were calculated
according to equation 2 (see main text for details).
(DOC)
Table S4 Evaluation of statistical significance of the differences
in mean relative fitness between wild type and AZT-resistant
variants for Donor 2 by a Student-Newman-Keuls test. Fitness
values are taken from Table S1c. Calculations were performed in
Graphpad Prism. The examples selected here for statistical
evaluation are discussed under results.
(DOC)
Table S5 Primers uses for the site-directed PCR to generate the
HIV-1 RTase mutants used in this study. Restriction sites are
underlined and bold, codons with the introduced mutantions are
underlined.
(DOC)
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